MX2017007318A - Metodos de prevencion, reduccion o tratamiento de degeneracion macular. - Google Patents

Metodos de prevencion, reduccion o tratamiento de degeneracion macular.

Info

Publication number
MX2017007318A
MX2017007318A MX2017007318A MX2017007318A MX2017007318A MX 2017007318 A MX2017007318 A MX 2017007318A MX 2017007318 A MX2017007318 A MX 2017007318A MX 2017007318 A MX2017007318 A MX 2017007318A MX 2017007318 A MX2017007318 A MX 2017007318A
Authority
MX
Mexico
Prior art keywords
methods
macular degeneration
preventing
reducing
treating macular
Prior art date
Application number
MX2017007318A
Other languages
English (en)
Inventor
K Mcvicar William
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of MX2017007318A publication Critical patent/MX2017007318A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos agonistas selectivos de adenosina A1, a composiciones farmacéuticas que comprenden tales compuestos y procedimientos de uso de tales compuestos para tratar, reducir o prevenir la degeneración macular senil.
MX2017007318A 2014-12-03 2015-12-02 Metodos de prevencion, reduccion o tratamiento de degeneracion macular. MX2017007318A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087080P 2014-12-03 2014-12-03
PCT/US2015/063450 WO2016090005A1 (en) 2014-12-03 2015-12-02 Methods of preventing, reducing or treating macular degeneration

Publications (1)

Publication Number Publication Date
MX2017007318A true MX2017007318A (es) 2017-08-25

Family

ID=56092394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007318A MX2017007318A (es) 2014-12-03 2015-12-02 Metodos de prevencion, reduccion o tratamiento de degeneracion macular.

Country Status (12)

Country Link
US (1) US20160158267A1 (es)
EP (1) EP3247715A1 (es)
JP (1) JP2018501219A (es)
KR (1) KR20170123605A (es)
CN (1) CN107406479A (es)
AU (1) AU2015358576A1 (es)
BR (1) BR112017011891A2 (es)
CA (1) CA2967446A1 (es)
EA (1) EA201790851A1 (es)
IL (1) IL252394A0 (es)
MX (1) MX2017007318A (es)
WO (1) WO2016090005A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102667208B1 (ko) * 2018-11-14 2024-05-20 스마일바이오텍 주하이 리미티드 안구 내 질환 또는 병증에 대한 동물 모델, 스크리닝 방법 및 치료 방법
JP7443361B2 (ja) * 2018-12-03 2024-03-05 珠海岐微生物科技有限公司 加齢黄斑変性症の治療方法
CN111658740B (zh) * 2020-06-19 2021-09-14 南京中医药大学 具有改善年龄相关性黄斑变性的药食两用组合物及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5203214B2 (ja) * 2005-11-30 2013-06-05 イノテック ファーマシューティカルズ コーポレイション プリン化合物およびその使用方法
US8828966B2 (en) * 2006-10-03 2014-09-09 Claire Mitchell Method for treatment of macular degeneration by modulating P2Y12 or P2X7 receptors
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
KR101757940B1 (ko) * 2009-05-01 2017-07-13 이노텍 파마슈티컬스 코포레이션 인간 안압을 감소시키는 방법
EP2493480A4 (en) * 2009-10-26 2013-04-10 Inotek Pharmaceuticals Corp OPHTHALMIC FORMULATION AND MANUFACTURING METHOD THEREFOR
AU2011203897B2 (en) * 2010-01-11 2016-11-17 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
SI2555775T1 (sl) * 2010-03-19 2017-05-31 Inotek Pharmaceuticals Corporation Kombinirani sestavki adenozin A1 agonistov in inhibitorjev karboanhidraze za zmanjšanje intraokularnega tlaka
DK2555776T3 (en) * 2010-03-19 2017-02-06 Inotek Pharmaceuticals Corp Combination Compositions of Adenosine A1 Agonists and Non-Selective Beta-Adrenoreceptor Blockers to Reduce Intraocular Pressure
US8501708B2 (en) * 2010-03-26 2013-08-06 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
US8476247B2 (en) * 2010-03-26 2013-07-02 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans
WO2014152723A1 (en) * 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
AU2014239232A1 (en) * 2013-03-15 2015-10-01 Inotek Pharmaceuticals Corporation A method of providing ocular neuroprotection

Also Published As

Publication number Publication date
CN107406479A (zh) 2017-11-28
JP2018501219A (ja) 2018-01-18
IL252394A0 (en) 2017-07-31
EP3247715A1 (en) 2017-11-29
KR20170123605A (ko) 2017-11-08
EA201790851A1 (ru) 2017-11-30
WO2016090005A1 (en) 2016-06-09
CA2967446A1 (en) 2016-06-09
AU2015358576A1 (en) 2017-06-22
BR112017011891A2 (pt) 2018-07-03
US20160158267A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
IL262007A (en) Modified aminopurine compounds, their compositions and methods of treatment using them
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
NZ724691A (en) Quinoline derivatives as smo inhibitors
IL253979B (en) Methods, preparations and kits for cancer treatment
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EP3294761A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12017501864A1 (en) Compositions and methods for treating autism
IL263697A (en) Compounds, preparations and methods for the treatment and/or prevention of cancer
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PH12016501393B1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
MX2017007318A (es) Metodos de prevencion, reduccion o tratamiento de degeneracion macular.